BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25211659)

  • 1. Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
    Michael M; Chander S; McKendrick J; MacKay JR; Steel M; Hicks R; Heriot A; Leong T; Cooray P; Jefford M; Zalcberg J; Bressel M; McClure B; Ngan SY
    Br J Cancer; 2014 Nov; 111(10):1924-31. PubMed ID: 25211659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Vestermark LW; Jensen HA; Pfeiffer P
    Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
    Wang CC; Liang JT; Tsai CL; Chen YH; Lin YL; Shun CT; Cheng JC
    World J Surg Oncol; 2014 Nov; 12():329. PubMed ID: 25373828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases.
    Bird T; Michael M; Bressel M; Chu J; Chander S; Cooray P; McKendrick J; Jefford M; Heriot A; Steel M; Leong T; Ngan S
    Acta Oncol; 2017 May; 56(5):646-652. PubMed ID: 28301974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial).
    Ng SP; Chu J; Chander S; Bressel M; McKendrick J; Wong R; Steel M; Murray WK; Leong T; Heriot A; Michael M; Ngan SY
    Radiother Oncol; 2021 Feb; 155():27-32. PubMed ID: 33065186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
    Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
    Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
    Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
    Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
    Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
    Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
    Maréchal R; Vos B; Polus M; Delaunoit T; Peeters M; Demetter P; Hendlisz A; Demols A; Franchimont D; Verset G; Van Houtte P; Van de Stadt J; Van Laethem JL
    Ann Oncol; 2012 Jun; 23(6):1525-30. PubMed ID: 22039087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
    Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
    Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.
    Bisschop C; van Dijk TH; Beukema JC; Jansen RLH; Gelderblom H; de Jong KP; Rutten HJT; van de Velde CJH; Wiggers T; Havenga K; Hospers GAP
    Ann Surg Oncol; 2017 Sep; 24(9):2632-2638. PubMed ID: 28560600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
    Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
    Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
    van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K
    Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
    Spigel DR; Bendell JC; McCleod M; Shipley DL; Arrowsmith E; Barnes EK; Infante JR; Burris HA; Greco FA; Hainsworth JD
    Clin Colorectal Cancer; 2012 Mar; 11(1):45-52. PubMed ID: 21840771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.